Scarica l'app Stockscreener
9.80
1.87%
0.18
Dopo l'orario di chiusura:
9.80
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BHVN Giù?
Forum
Previsione
Biohaven Ltd Borsa (BHVN) Ultime notizie
Aug Spikes: What is the long term forecast for Biohaven Ltd stock2026 Update & Consistent Profit Trade Alerts - baoquankhu1.vn
BHVN PE Ratio & Valuation, Is BHVN Overvalued - intellectia.ai
BHVN Financials: Revenue Breakdown, Margins & Competitor Comparison - intellectia.ai
Multiple System Atrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Ionis Pharma, Biohaven Pharma, Lundbeck A/S, Alterity Therapeutics, Theravance Biopharma, Brain Neuro - Barchart.com
Why Biohaven (BHVN) Is Up 11.7% After Fully Enrolling Its Phase 2 Obesity Drug Trial - Sahm
Biohaven Ltd. (BHVN) stock price, news, quote and history - Yahoo Finance UK
Citigroup Forecasts Strong Price Appreciation for Biohaven (NYSE:BHVN) Stock - MarketBeat
Citi Maintains Biohaven(BHVN.US) With Buy Rating, Raises Target Price to $17 - Moomoo
BHVN SEC FilingsBiohaven 10-K, 10-Q, 8-K Forms - Stock Titan
Biohaven Ltd. (BHVN) Stock Price, News, Quote & History - Yahoo! Finance Canada
BHVN Stock Price, Quote & Chart | BIOHAVEN LTD (NYSE:BHVN) - ChartMill
Biohaven (NYSE:BHVN) Shares Up 10.5%Here's Why - MarketBeat
Biohaven Jumps 10.9% Amid Robust Intraday Rally—What’s Driving This Upswing? - Bitget
Biohaven (BHVN) Fuels Confidence With Encouraging Azetukalner Data - Insider Monkey
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - MSN
Aug Final Week: Can Biohaven Ltd stock outperform in a bear market2026 Price Targets & Smart Investment Allocation Tips - baoquankhu1.vn
Investment Recap: Can Biohaven Ltd deliver alpha2026 Update & Accurate Intraday Trade Tips - baoquankhu1.vn
Biohaven (BHVN) completes enrollment in phase 2 obesity study of taldefgrobep alfa - MSN
Breakout Zone: Can Biohaven Ltd be recession proofDip Buying & Weekly High Return Stock Forecasts - baoquankhu1.vn
Can Biohaven (BHVN) Redefine Obesity Treatment By Targeting Lean Mass Preservation With Taldefgrobep? - finance.yahoo.com
Gains Recap: How does Biohaven Ltd score in quality rankingsLayoff News & Detailed Earnings Play Alerts - baoquankhu1.vn
Market Pulse: What are analysts price targets for Biohaven Ltd2026 Volatility Report & Risk Managed Trade Strategies - baoquankhu1.vn
The Technical Signals Behind (BHVN) That Institutions Follow - Stock Traders Daily
Biohaven shares edge higher after completing enrollment in obesity drug trial - MSN
Biohaven (BHVN) Completes Enrollment in Phase 2 Obesity Study of Taldefgrobep Alfa - Insider Monkey
Biohaven (NYSE:BHVN) Trading 6.2% HigherHere's Why - MarketBeat
Can Biohaven (BHVN) Redefine Obesity Treatment By Prioritizing Muscle Preservation Over Pure Weight Loss? - simplywall.st
JPMorgan Chase & Co. Sells 1,236,587 Shares of Biohaven Ltd. $BHVN - marketbeat.com
Assessing Biohaven (BHVN) Valuation As Losses Persist And Price To Book Hits 25x - simplywall.st
Biohaven Shares Drop 70%, Yet a Fund’s Fresh $6 Million Investment Hints at Possible Recovery - Bitget
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential - The Motley Fool
Movement Recap: What is the long term forecast for Biohaven Ltd stockGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Biohaven’s robust cash reserves and unique degrader strategy ignite a strong value opportunity, with crucial 2026 clinical trials approaching - Bitget
Biohaven's 2026 Pivotal Trial Countdown: Can Capital Discipline Unlock a High-Risk, High-Reward Moat? - Bitget
DAFNA Capital Management Increases Biohaven Ltd. Investment in 2025News and Statistics - IndexBox
Biohaven Ltd.: Fundamental Analysis and Financial Ratings | BHVN34 | BRBHVNBDR001 - marketscreener.com
Biohaven completes enrollment in obesity drug trial By Investing.com - Investing.com India
Biohaven (NASDAQ: BHVN) director reports gifting 34,684 shares, adds family trust - Stock Titan
Risk Off: What is the long term forecast for Biohaven Ltd stock2026 Market WrapUp & Precise Swing Trade Alerts - baoquankhu1.vn
Biohaven Therapeutics discloses prodrugs of betahistine - BioWorld MedTech
Biohaven Ltd. Completes Enrollment In Phase 2 Obesity Study With Taldefgrobep Alfa - marketscreener.com
Biohaven completes enrollment in obesity drug trial - Investing.com
Biohaven stock rises as obesity trial completes enrollment - Investing.com UK
Biohaven's Phase 2 Obesity Study with Taldefgrobep Alfa, a Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment - PR Newswire
Biohaven has completed enrollment for its obesity study—However, the market still hasn't factored in the potential risk of the trial not succeeding - Bitget
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):